Diabetes mellitus is a complex and progressive disease associated with significant morbidity and mortality. According to the American diabetes association: “Diabetes was the seventh leading cause of death in the United States in 2015 “. However, the US is not the only country which has this problem, it is a huge and costive challenge around the world. The good news is that Diabetes type II is reversible if the patient can maintain a healthy lifestyle. So, we would like to build this platform to improve the quality of life for those patients.
What it does
- improve patient adherence
- draw data from noninvasive mobile devices and other applications
- share data with health providers and loved one
- video/audio intervention session
- reminder function of taking medication, doing exercise, etc.
- predict sugar level of patients and send the alert them when necessary
- gather data under the permission of patients for further study
How we built it
Twilio Account Security can be used to generate and verify (authenticate) user tokens. This can be used prior to their video chat. Twilio Video service can be used to connect people. Also, Twilio has a voice recognition (voice to text)which is a part of the voice services. For example, when a voice call is made, the user can say a word to their phone. Twilio voice receives the voice word, converts it into text and sends a callback to the program to handle the word (or phrase).
Challenges we ran into
- time limitation
- technical challenge-We had a dilemma of choosing a suitable voice-activated tool. Fortunately, we solved it.
Accomplishments that we're proud of
We build everything from scratch in a rather short time thanks to those warm support we got from experienced healthcare providers and technical experts.
What we learned
The skills needed to implement from ideas to real project
What's next for Sugar
- Build it
- Collaborate with top-level universities for further research
- We have made an initial agreement with ShengJing hospital which belongs to China Medical University (PRC), that we could do the device trial on two internal medicine wards (160 beds) once we are done.
- Apply for fundings